



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

## BIB DATA SHEET

CONFIRMATION NO. 7811

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/509,521	06/10/2005	254	1626	PG4793USw
<b>RULE</b>				
<b>APPLICANTS</b> John Spencer Cook, Hertfordshire, UNITED KINGDOM; Robert Philip Landon, Hertfordshire, UNITED KINGDOM; Andrew John Walker, Hertfordshire, UNITED KINGDOM; Mark Wilkinson, Hertfordshire, UNITED KINGDOM;				
<b>** CONTINUING DATA *****</b> This application is a 371 of PCT/EP03/03345 03/27/2003				
<b>** FOREIGN APPLICATIONS *****</b> UNITED KINGDOM 0207432.6 03/28/2002				
<b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b>				
Foreign Priority claimed	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	<b>STATE OR COUNTRY</b>	<b>SHEETS DRAWINGS</b>
35 USC 119(a-d) conditions met	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		UNITED KINGDOM	2
Verified and	/SAMANTHA L SHTERENGARTS/ Examiner's Signature	Initials		15
Acknowledged				1
<b>ADDRESS</b> GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B482 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398 UNITED STATES				
<b>TITLE</b> Benzenesulphonate salt of a morpholine urea derivative for use as a cor-3 antagonist in the treatment of inflammatory conditions				
<b>FILING FEE RECEIVED</b> 1006	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			<input type="checkbox"/> All Fees
				<input type="checkbox"/> 1.16 Fees (Filing)
				<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
				<input type="checkbox"/> 1.18 Fees (Issue)
				<input type="checkbox"/> Other _____
				<input type="checkbox"/> Credit